ICAAC: Three's company for HIV

All 16 drugs marketed to treat HIV inhibit viral replication either by inhibiting the viral reverse transcriptase or protease. But reports at last week's Interscience Conference on Antimicrobial Agents and Chemotherapy are showing that these two viral targets now have legitimate company.

Though much of the attention at ICAAC was focused on Fuzeon enfuvirtide (formerly T-20) from Trimeris Inc. and partner Roche, the potential of agents targeting other aspects of HIV replication was not lost on conference attendees...